These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

245 related articles for article (PubMed ID: 31313971)

  • 21. Therapeutic options for visceral leishmaniasis.
    Monge-Maillo B; López-Vélez R
    Drugs; 2013 Nov; 73(17):1863-88. PubMed ID: 24170666
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The advantages of nanomedicine in the treatment of visceral leishmaniasis: between sound arguments and wishful thinking.
    Matha K; Calvignac B; Gangneux JP; Benoit JP
    Expert Opin Drug Deliv; 2021 Apr; 18(4):471-487. PubMed ID: 33217254
    [No Abstract]   [Full Text] [Related]  

  • 23. Characterization and evaluation of BNIPDaoct-loaded PLGA nanoparticles for visceral leishmaniasis: in vitro and in vivo studies.
    Costa Lima SA; Resende M; Silvestre R; Tavares J; Ouaissi A; Lin PK; Cordeiro-da-Silva A
    Nanomedicine (Lond); 2012 Dec; 7(12):1839-49. PubMed ID: 22812711
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Using focused pharmacovigilance for ensuring patient safety against antileishmanial drugs in Bangladesh's National Kala-azar Elimination Programme.
    Hossain MS; Kumar A; Hossain AFMA; Mahshin M; Sharma A; Hossain MA; Sharma V; Haque R; Shamsuzzaman AKM; Maruf S; Ghosh P; Ahuja V; Mondal D
    Infect Dis Poverty; 2018 Aug; 7(1):80. PubMed ID: 30099967
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Understanding the transmission dynamics of Leishmania donovani to provide robust evidence for interventions to eliminate visceral leishmaniasis in Bihar, India.
    Cameron MM; Acosta-Serrano A; Bern C; Boelaert M; den Boer M; Burza S; Chapman LA; Chaskopoulou A; Coleman M; Courtenay O; Croft S; Das P; Dilger E; Foster G; Garlapati R; Haines L; Harris A; Hemingway J; Hollingsworth TD; Jervis S; Medley G; Miles M; Paine M; Picado A; Poché R; Ready P; Rogers M; Rowland M; Sundar S; de Vlas SJ; Weetman D
    Parasit Vectors; 2016 Jan; 9():25. PubMed ID: 26812963
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Visceral leishmaniasis in Saudi Arabia: From hundreds of cases to zero.
    Abuzaid AA; Aldahan MA; Helal MAA; Assiri AM; Alzahrani MH
    Acta Trop; 2020 Dec; 212():105707. PubMed ID: 32950481
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Detection of asymptomatic Leishmania infection in Bangladesh by antibody and antigen diagnostic tools shows an association with post-kala-azar dermal leishmaniasis (PKDL) patients.
    Owen SI; Hossain F; Ghosh P; Chowdhury R; Hossain MS; Jewell C; Cruz I; Picado A; Mondal D; Adams ER
    Parasit Vectors; 2021 Feb; 14(1):111. PubMed ID: 33597000
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Liposomal amphotericin B in drug-resistant visceral leishmaniasis.
    Davidson RN; Croft SL; Scott A; Maini M; Moody AH; Bryceson AD
    Lancet; 1991 May; 337(8749):1061-2. PubMed ID: 1673494
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of a Multiplexed Assay for Detection of
    Abeijon C; Alves F; Monnerat S; Wasunna M; Mbui J; Viana AG; Bueno LL; Siqueira WF; Carvalho SG; Agrawal N; Fujiwara R; Sundar S; Campos-Neto A
    J Clin Microbiol; 2019 May; 57(5):. PubMed ID: 30787142
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Polyester nanomedicines for visceral leishmaniasis treatment.
    Sikarwar M; Mishra VS; Tiwari P; Gupta M; Dholpuria S; Gupta PK
    Nanomedicine (Lond); 2023 Sep; 18(22):1515-1518. PubMed ID: 37724503
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nonmigrant children with visceral leishmaniasis from the nonendemic area of Uttarakhand.
    Mathur SB; Arya AK
    J Trop Pediatr; 2014 Aug; 60(4):322-5. PubMed ID: 24531375
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Road-map of pre-clinical treatment for Visceral Leishmaniasis.
    Mazire P; Agarwal V; Roy A
    Drug Dev Res; 2022 Apr; 83(2):317-327. PubMed ID: 34962315
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Xenodiagnosis to address key questions in visceral leishmaniasis control and elimination.
    Singh OP; Hasker E; Boelaert M; Sacks D; Sundar S
    PLoS Negl Trop Dis; 2020 Aug; 14(8):e0008363. PubMed ID: 32790716
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Visceral leishmaniasis caused by Leishmania (Leishmania) amazonensis associated with Hodgkin's lymphoma.
    Porto VBG; Carvalho LB; Buzo BF; Litvoc MN; Santos ACS; Rocci RA; Soares SRC; Zampieri RA; Duarte MIS; Lindoso JAL
    Rev Inst Med Trop Sao Paulo; 2022; 64():e51. PubMed ID: 36074446
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Post Kala-Azar dermal leishmaniasis following treatment with 20 mg/kg liposomal amphotericin B (Ambisome) for primary visceral leishmaniasis in Bihar, India.
    Burza S; Sinha PK; Mahajan R; Sanz MG; Lima MA; Mitra G; Verma N; Das P
    PLoS Negl Trop Dis; 2014; 8(1):e2611. PubMed ID: 24392171
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nanoliposomal artemisinin for the treatment of murine visceral leishmaniasis.
    Want MY; Islammudin M; Chouhan G; Ozbak HA; Hemeg HA; Chattopadhyay AP; Afrin F
    Int J Nanomedicine; 2017; 12():2189-2204. PubMed ID: 28356736
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Lactoferrin-modified Betulinic Acid-loaded PLGA nanoparticles are strong anti-leishmanials.
    Halder A; Shukla D; Das S; Roy P; Mukherjee A; Saha B
    Cytokine; 2018 Oct; 110():412-415. PubMed ID: 29784509
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Development and comparative evaluation of two antigen detection tests for Visceral Leishmaniasis.
    Vallur AC; Tutterrow YL; Mohamath R; Pattabhi S; Hailu A; Abdoun AO; Ahmed AE; Mukhtar M; Salam MA; Almeida ML; Almeida RP; Mondal D; Albertini A; Ghalib H; Duthie MS; Reed SG
    BMC Infect Dis; 2015 Sep; 15():384. PubMed ID: 26395447
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Chemotherapeutics of visceral leishmaniasis: present and future developments.
    Sundar S; Singh A
    Parasitology; 2018 Apr; 145(4):481-489. PubMed ID: 29215329
    [TBL] [Abstract][Full Text] [Related]  

  • 40. An overview of visceral leishmaniasis elimination program in India: a picture imperfect.
    Gurunath U; Joshi R; Agrawal A; Shah V
    Expert Rev Anti Infect Ther; 2014 Aug; 12(8):929-35. PubMed ID: 24930676
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.